1
|
Park Y, Jung J, Jeong S, van Ee A, Garza LA, Jang M, Kim D, Park J. Reversine enhances skin barrier functions by suppressing the IL-4- and IL-13-mediated STAT6 pathway. J Dermatol Sci 2023; 111:71-73. [PMID: 37442736 PMCID: PMC10529134 DOI: 10.1016/j.jdermsci.2023.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 06/12/2023] [Accepted: 06/21/2023] [Indexed: 07/15/2023]
Affiliation(s)
- Yukyung Park
- Graduate School of Energy/Biotechnology, Dongseo University, Busan, Republic of Korea
| | - Janghwan Jung
- Department of Dermatology, Kosin University College of Medicine, Busan, Republic of Korea
| | - Sunmun Jeong
- Department of Dermatology, Kosin University College of Medicine, Busan, Republic of Korea
| | - Amy van Ee
- Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Luis A Garza
- Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Minsoo Jang
- Department of Dermatology, Kosin University College of Medicine, Busan, Republic of Korea
| | - Dongwon Kim
- Graduate School of Energy/Biotechnology, Dongseo University, Busan, Republic of Korea; Department of Bio-Chemical Engineering, College of Bio-Health Convergence, Dongseo University, Busan, Republic of Korea.
| | - Jongbin Park
- Department of Dermatology, Kosin University College of Medicine, Busan, Republic of Korea.
| |
Collapse
|
2
|
Şenol H, Şahin RB, Mercümek B, Kapucu HB, Hacıosmanoğlu E, Dinç HÖ, Yüksel Mayda P. Synthesis of ursolic acid arylidene-hydrazide hybrid compounds and investigation of their cytotoxic and antimicrobial effects. Nat Prod Res 2023; 37:2500-2507. [PMID: 35275500 DOI: 10.1080/14786419.2022.2051170] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 03/03/2022] [Accepted: 03/04/2022] [Indexed: 12/24/2022]
Abstract
In this study, 13 new hybrid compounds (7a-m) were synthesised starting from ursolic acid, and their cytotoxic activities were investigated on the BEAS-2B and A549 cell lines. In addition, the synthesised compounds were tested against Staphylococcus aureus, Escherichia coli, and Candida albicans to determine their anti-microbial properties. The hybrid compounds that exhibited the lowest cytotoxicity against the BEAS-2B were 7k, 7b, and 7g. The cytotoxicity of the compounds against A549 was evaluated, the IC50 value of 7k, 7b, and 7g are found as 0.15 µM, 0.31 µM, and 0.26 µM, respectively. The results showed that the selectivity of 7k was 7 times higher than doxorubicin against the A549 cells. According to the antimicrobial activity studies 7c is found as the most effective compound against S. aureus. Almost all compounds showed a similar inhibition potential against E. coli and C. albicans.
Collapse
Affiliation(s)
- Halil Şenol
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, Turkey
| | | | | | - Halil Burak Kapucu
- Faculty of Medicine, Department of Biophysics, Bezmialem Vakif University, Turkey
| | - Ebru Hacıosmanoğlu
- Faculty of Medicine, Department of Biophysics, Bezmialem Vakif University, Turkey
| | - Harika Öykü Dinç
- Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Bezmialem Vakif University, Turkey
| | - Pelin Yüksel Mayda
- Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Bezmialem Vakif University, Turkey
| |
Collapse
|
3
|
Rajabian N, Choudhury D, Ikhapoh I, Saha S, Kalyankar AS, Mehrotra P, Shahini A, Breed K, Andreadis ST. Reversine ameliorates hallmarks of cellular senescence in human skeletal myoblasts via reactivation of autophagy. Aging Cell 2023; 22:e13764. [PMID: 36625257 PMCID: PMC10014065 DOI: 10.1111/acel.13764] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 10/20/2022] [Accepted: 12/08/2022] [Indexed: 01/11/2023] Open
Abstract
Cellular senescence leads to the depletion of myogenic progenitors and decreased regenerative capacity. We show that the small molecule 2,6-disubstituted purine, reversine, can improve some well-known hallmarks of cellular aging in senescent myoblast cells. Reversine reactivated autophagy and insulin signaling pathway via upregulation of Adenosine Monophosphate-activated protein kinase (AMPK) and Akt2, restoring insulin sensitivity and glucose uptake in senescent cells. Reversine also restored the loss of connectivity of glycolysis to the TCA cycle, thus restoring dysfunctional mitochondria and the impaired myogenic differentiation potential of senescent myoblasts. Altogether, our data suggest that cellular senescence can be reversed by treatment with a single small molecule without employing genetic reprogramming technologies.
Collapse
Affiliation(s)
- Nika Rajabian
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Debanik Choudhury
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Izuagie Ikhapoh
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Shilpashree Saha
- Department of Biomedical EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Aishwarya S. Kalyankar
- Department of Biomedical EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Pihu Mehrotra
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Aref Shahini
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Kendall Breed
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| | - Stelios T. Andreadis
- Department of Chemical and Biological EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
- Department of Biomedical EngineeringUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
- Center of Excellence in Bioinformatics and Life SciencesUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
- Cell, Gene and Tissue Engineering (CGTE) Center, School of Engineering and Applied SciencesUniversity at Buffalo, State University of New YorkAmherstNew YorkUSA
| |
Collapse
|
4
|
Aza-Reversine Promotes Reprogramming of Lung (MRC-5) and Differentiation of Mesenchymal Cells into Osteoblasts. MATERIALS 2021; 14:ma14185385. [PMID: 34576609 PMCID: PMC8467999 DOI: 10.3390/ma14185385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 09/10/2021] [Accepted: 09/14/2021] [Indexed: 11/21/2022]
Abstract
Reversine or 2-(4-morpholinoanilino)-N6-cyclohexyladenine was originally identified as a small organic molecule that induces dedifferentiation of lineage-committed mouse myoblasts, C2C12, and redirects them into lipocytes or osteoblasts under lineage-specific conditions (LISCs). Further, it was proven that this small molecule can induce cell cycle arrest and apoptosis and thus selectively lead cancer cells to cell death. Further studies demonstrated that reversine, and more specifically the C2 position of the purine ring, can tolerate a wide range of substitutions without activity loss. In this study, a piperazine analog of reversine, also known as aza-reversine, and a biotinylated derivative of aza-reversine were synthesized, and their potential medical applications were investigated by transforming the endoderm originates fetal lung cells (MRC-5) into the mesoderm originated osteoblasts and by differentiating mesenchymal cells into osteoblasts. Moreover, the reprogramming capacity of aza-reversine and biotinylated aza-reversine was investigated against MRC-5 cells and mesenchymal cells after the immobilization on PMMA/HEMA polymeric surfaces. The results showed that both aza-reversine and the biofunctionalized, biotinylated analog induced the reprogramming of MRC-5 cells to a more primitive, pluripotent state and can further transform them into osteoblasts under osteogenic culture conditions. These molecules also induced the differentiation of dental and adipose mesenchymal cells to osteoblasts. Thus, the possibility to load a small molecule with useful “information” for delivering that into specific cell targets opens new therapeutic personalized applications.
Collapse
|
5
|
Hirakata C, Lima K, De Almeida BO, De Miranda LBL, Florêncio KGD, Furtado LC, Costa-Lotufo LV, Machado-Neto JA. Targeting glioma cells by antineoplastic activity of reversine. Oncol Lett 2021; 22:610. [PMID: 34188712 PMCID: PMC8227489 DOI: 10.3892/ol.2021.12871] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Accepted: 06/02/2021] [Indexed: 12/30/2022] Open
Abstract
Gliomas are the most common type of primary central nervous system tumors and despite great advances in understanding the molecular basis of the disease very few new therapies have been developed. Reversine, a synthetic purine analog, is a multikinase inhibitor that targets aurora kinase A (AURKA) and aurora kinase B (AURKB). In gliomas, a high expression of AURKA or AURKB is associated with a malignant phenotype and a poor prognosis. The present study investigated reversine-related cellular and molecular antiglioma effects in HOG, T98G and U251MG cell lines. Gene and protein expression were assessed by reverse transcription-quantitative PCR and western blotting, respectively. For functional assays, human glioma cell lines (HOG, T98G and U251MG) were exposed to increasing concentrations of reversine (0.4–50 µM) and subjected to various cellular and molecular assays. Reversine reduced the viability and clonogenicity in a dose- and/or time-dependent manner in all glioma cells, with HOG (high AURKB-expression) and T98G (high AURKA-expression) cells being more sensitive compared with U251MG cells (low AURKA- and AURKB-expression). Notably, HOG cells presented higher levels of polyploidy, while T98G presented multiple mitotic spindles, which is consistent with the main regulatory functions of AURKB and AURKA, respectively. In molecular assays, reversine reduced AURKA and/or AURKB expression/activity and increased DNA damage and apoptosis markers, but autophagy-related proteins were not modulated. In conclusion, reversine potently induced mitotic catastrophe and apoptosis in glioma cells and higher basal levels of aurora kinases and genes responsive to DNA damage and may predict improved antiglioma responses to the drug. Reversine may be a potential novel drug in the antineoplastic arsenal against gliomas.
Collapse
Affiliation(s)
- Camila Hirakata
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - Keli Lima
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - Bruna Oliveira De Almeida
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - Lívia Bassani Lins De Miranda
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - Katharine Gurgel Dias Florêncio
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Ceará, CEP 60440-900, Brazil
| | - Luciana Costa Furtado
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - Leticia Veras Costa-Lotufo
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| | - João Agostinho Machado-Neto
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, CEP 05508-900, Brazil
| |
Collapse
|